Climb Bio, Inc. CLYM US — Net Income Loss

Other geography segments

Similar metrics at other companies

THMUS — Net Income Loss

-$610.01K-46.6%

AMCIEurope — Net Income Loss

$238+101%

THMCA — Net Income Loss

$2.88M+1,240%

FTE

FTEKCN — Net Income Loss

-$13K+27.8%

NAMSNet Income Loss

-$64.14M-269%

OFIXNet Income Loss

-$15.8M-12.2%

FAQ

What is Climb Bio, Inc.'s US — net income loss?

Climb Bio, Inc. (CLYM) reported US — net income loss of -$14.89M in Q4 2025.

How has Climb Bio, Inc.'s US — net income loss changed year-over-year?

Climb Bio, Inc.'s US — net income loss increased by 11.3% year-over-year, from -$16.78M to -$14.89M.

What is the long-term trend for Climb Bio, Inc.'s US — net income loss?

Over 4 years (2021 to 2025), Climb Bio, Inc.'s US — net income loss has grown at a 45.5% compound annual growth rate (CAGR), from -$13.31M to -$59.58M.

What does US — net income loss mean?

This metric represents the net profit or loss generated specifically by the company's operations within the United States geographic segment. It reflects the bottom-line financial performance after accounting for all segment-specific revenues, research and development expenditures, and operating costs. Monitoring this figure helps investors assess the financial sustainability and resource consumption of the company's primary domestic clinical development activities.